Here's Why Danaher Stock Surged Today
's (NYSE: DHR) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings report shows that it's set to return to its long-term growth track.
The good news encouraged investors to bid the stock up by more than 7% in trading before 10 a.m. ET today.
As you might expect from a biotechnology, life sciences, and diagnostics company, Danaher's core revenue and earnings have bounced around in recent years due to the pandemic. Not only did Danaher manufacture PCR tests used to detect COVID-19, but it also sold life sciences equipment used to research vaccines.
Source Fool.com
Danaher Corp. Stock
€165.15
0.520%
With 54 Buy predictions and not a single Sell prediction Danaher Corp. is an absolute favorite of our community.
With a target price of 210 € there is a positive potential of 27.16% for Danaher Corp. compared to the current price of 165.15 €.
